TY - JOUR
T1 - Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure
AU - Feldman, Arthur M.
AU - Becker, Lewis C.
AU - Llewellyn, Michaelene P.
AU - Baughman, Kenneth L.
N1 - Funding Information:
by a Clinician Scientist Faculty W. Mellon Foundation (Dr. Feldman) Company, Osaka, Japan. for publication Dec. 23, 1987; accepted May requests: Arthur M. Feldman, MD, PhD, Hopkins Hospital. 725 N. Wolfe St., Baltimore,
PY - 1988/9
Y1 - 1988/9
N2 - OPC-8212 is a new positive inotrope with a unique mechanism of action. To assess its clinical utility we administered 60 mg/day for 30 days to 10 patients with overt congestive heart fallure, who had substantial limitations in exercise pertormance despite treatment with conventional therapy. Patients were evaluated by simultaneous respiratory gas exchange and radionuclide ventriculography measurements during graded maximal exercise testing. Improvement was demonstrated in both peak oxygen uptake and radionuclide-determined cardiac index after 30 days of treatment with OPC-8212. These changes were not associated with alterations in heart rate at rest or during peak exercise. Furthermore OPC-8212 significantly decreased ventricular ectopy in our patients. However, two patients had possible hematologic toxicity with prolonged use. The results of the present phase II study suggest that a larger randomized double-blind placebo study to evaluate the safety and clinical efficacy of this drug is warranted.
AB - OPC-8212 is a new positive inotrope with a unique mechanism of action. To assess its clinical utility we administered 60 mg/day for 30 days to 10 patients with overt congestive heart fallure, who had substantial limitations in exercise pertormance despite treatment with conventional therapy. Patients were evaluated by simultaneous respiratory gas exchange and radionuclide ventriculography measurements during graded maximal exercise testing. Improvement was demonstrated in both peak oxygen uptake and radionuclide-determined cardiac index after 30 days of treatment with OPC-8212. These changes were not associated with alterations in heart rate at rest or during peak exercise. Furthermore OPC-8212 significantly decreased ventricular ectopy in our patients. However, two patients had possible hematologic toxicity with prolonged use. The results of the present phase II study suggest that a larger randomized double-blind placebo study to evaluate the safety and clinical efficacy of this drug is warranted.
UR - http://www.scopus.com/inward/record.url?scp=0023678377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023678377&partnerID=8YFLogxK
U2 - 10.1016/0002-8703(88)90336-5
DO - 10.1016/0002-8703(88)90336-5
M3 - Article
C2 - 3046278
AN - SCOPUS:0023678377
SN - 0002-8703
VL - 116
SP - 771
EP - 777
JO - American heart journal
JF - American heart journal
IS - 3
ER -